CYP2C9 allele variants in Chinese hypertension patients and healthy controls

Clinica Chimica Acta

Volumn 348, Issue 1-2, 2004, Pages 57-61

  Yu, Bang Ning ^a   Luo, Chen Hui ^a   Wang, Dan ^a   Wang, An ^a   Li, Zhi ^a   Zhang, Wei ^a   Mo, Wei ^a   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

CYP2C9; Gender; Gene mutation; Hypertension; Polymerase chain reaction

Indexed keywords

CYTOCHROME P450 2C9; ENZYME VARIANT;

ADULT; AGED; ALLELE; ARTICLE; CHINESE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC POLYMORPHISM; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE;

AGED; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; FEMALE; GENE FREQUENCY; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 4444238679     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2004.04.028     Document Type: Article

References (21)

1. Nasu K., Kubota T., Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics. 7(5):Oct. 1997;405-409
2. Aithal G.P., Day C.P., Kesteven P.J., Daly A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 353:1999;717-719
3. Brandolese R., Scordo M.G., Spina E., Gusella M., Padrini R. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. Clin. Pharmacol. Ther. 70:2001;391-394
4. Yasar U., Forslund C., Tybring G., Dorado P., LLerena A., Sjoqvist F., et al. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin. Pharmacol. Ther. 71:2002;89-98
5. Dorado P., Berecz R., Norberto M.J., Yasar U., Dahl M.L., LLerena A. CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur. J. Clin. Pharmacol. 59(3):2003(Jul.);221-225
6. Daikh B.E., Lasker J.M., Raucy J.L., Koop D.R. Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. J. Pharmacol. Exp. Ther. 271:1994;1427-1433
7. Fisslthaler B., Popp R., Kiss L., Potente M., Harder D.R., Fleming I., et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature. 401:1999;493-497
8. Quilley J., McGiff J.C. Is EDHF an epoxyeicosatrienoic acid? Trends Pharmacol. Sci. 21:2000;121-124
9. + channels. Circ. Res. 83:1998;501-507
10. Mancy A., Dijols S., Poli S., Guengerich P., Mansuy D. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9. Biochemistry. 35:1996;16205-16212
11. Sai Y., Dai R., Yang T.J., Krausz K.W., Gonzalez F.J., Gelboin H.V., et al. Assessment of specificity of eight chemical inhibitors using cDNA expressed cytochromes P450. Xenobiotica. 30:2000;327-343
12. Lou Y.C., Ying L., Bertilsson L., Sjoqvist F. Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet. 2:1987;852-853
13. Kidd R.S., Curry T.B., Gallagher S., Edeki T., Blaisdell J., Goldstein J.A. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics. 11:2001;803-808
14. Stubbins M.J., Harries L.W., Smith G., Tarbit M.H., Wolf C.R. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics. 6:1996;429-439
15. Yasar U., Eliasson E., Dahl M.L., Johansson I., Ingelman-Sundberg M., Sjoqvist F. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem. Biophys. Res. Commun. 254:1999;628-631
16. Garcia-Martin E., Martinez C., Ladero J.M., Gamito F.J., Agundez J.A. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population. Eur. J. Clin. Pharmacol. 57:2001;47-49
17. Fleming I. Cytochrome p450 and vascular homeostasis. Circ. Res. 89:2001;753-762
18. Tabrizi A.R., Zehnbauer B.A., Borecki I.B., McGrath S.D., Buchman T.G., Freeman B.D. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J. Am. Coll. Surg. 194(3):2002(Mar.);267-273
19. Rademaker M. Do women have more adverse drug reactions? Am. J. Clin. Dermatol. 2(6):2001;349-351. [Review]
20. Yasar U., Bennet A.M., Eliasson E., Lundgren S., Wiman B., De Faire U., et al. Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics. 13(12):2003(Dec.);715-720
21. Schwartz J.B. The influence of sex on pharmacokinetics. Clin. Pharmacokinet. 42(2):2003;107-121. [Review]